Dogwood Therapeutics (DWTX) Interest & Investment Income (2023 - 2026)
Dogwood Therapeutics (DWTX) posted Interest & Investment Income of $66349.0 for Q2 2026, down 14.22% on a QoQ basis from $77350.0 in Q1 2026, and down 40.43% year-over-year from $111379.0 in Q2 2025.
Powered by 
Analysis
Dogwood Therapeutics (DWTX) Interest & Investment Income (2023 - 2026) Analysis & Trends
Dogwood Therapeutics has reported Interest & Investment Income for 4 years, with the latest figure at $66349.0 in Q2 2026.
- On a quarterly basis, Interest & Investment Income fell 40.43% year-over-year to $66349.0 in Q2 2026; TTM through Jun 2026 was $276348.0, a 261.93% increase from a year earlier, with the FY2025 full-year figure at $96938.0, up 205.15% from the prior year.
- Interest & Investment Income was $66349.0 for Q2 2026 at Dogwood Therapeutics, down from $77350.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $111379.0 in Q2 2025, with the low at -$155437.0 in Q4 2024.
- Average Interest & Investment Income over 4 years is $19917.4, with a median of $36313.0 recorded in 2023.
- The largest YoY upside for Interest & Investment Income was 457.15% in 2025 against a maximum downside of 746.1% in 2025.
- Over 4 years, Interest & Investment Income stood at $34953.0 in 2023, then plunged by 544.7% to -$155437.0 in 2024, then jumped by 133.5% to $52067.0 in 2025, then rose by 27.43% to $66349.0 in 2026.
- The last three Interest & Investment Income figures came in at $66349.0 (Q2 2026), $77350.0 (Q1 2026), and $52067.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 120.60 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -48.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 48.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 67.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 36.92 Mn |
| 10 | Dogwood Therapeutics | 65.53 Mn | 65.53 Mn | - | 66,349.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 66,349.00 |
| Mar 31, 2026 | 77,350.00 |
| Dec 31, 2025 | 52,067.00 |
| Sep 30, 2025 | 80,582.00 |
| Jun 30, 2025 | 111,379.00 |
| Mar 31, 2025 | -147,090.00 |
| Dec 31, 2024 | -155,437.00 |
| Sep 30, 2024 | 20,488.00 |
| Jun 30, 2024 | 19,991.00 |
| Mar 31, 2024 | 22,766.00 |
| Dec 31, 2023 | 34,953.00 |
| Sep 30, 2023 | 39,215.00 |
| Jun 30, 2023 | 36,313.00 |